ZELIRA THERAPEUTICS LIMITED
ASX:ZLDPharmaceuticals, Biotechnology & Life SciencesSuspended from quotationToday’s holders own 91.3% of what they think they own, once every option and right converts.
Not rated — the company is suspended from quotation
This company is suspended from ASX quotation. Scoring is paused until it resumes trading. Not rated means no assessment — not low risk.
ZELIRA THERAPEUTICS LIMITED's ordinary share count rose 10.5% between April 2025 and July 2026, its latest share-count filing, to 13M shares. The company raised capital once in the past 24 months, a convertible note issue in November 2025 that raised A$728K. Options and rights on issue could convert into 1M new shares, equal to 9.5% of the current share count, none of which are in the money; the expiry date for these securities is not on record. No later cash report is on record, so no funding-runway figure applies. No proposed securities issues are pending.
Quick answers · 5
When did ZLD last raise capital?
The last capital raise in Zelira Therapeutics's filings is Convertible Note Issue of $728k announced 19 Nov 2025, one of 1 cash raises in 24 months.
How much placement capacity does ZLD have left?
None of the 15% placement capacity counted as used in the last 12 months (estimate). Under ASX Listing Rule 7.1 a company may place up to 15% of its shares in 12 months without shareholder approval.
How much cash does ZLD have?
In its quarterly cash report for the quarter ended 30 June 2026, Zelira Therapeutics reported $62k of cash and estimated 0.4 quarters of funding available at its current rate of spending. That is the company's own estimate.
How many options and rights does ZLD have outstanding?
Unexercised options and rights equal 9.5% of Zelira Therapeutics's shares on issue.
How much has ZLD's share count grown?
Zelira Therapeutics has 13.1M shares on issue as at 28 Oct 2026, up 10.5% over 24 months according to its Appendix 2A filings.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 5 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 2 July 2026 | 3H · cancellation | ZLD : ORDINARY FULLY PAID | 11.9M | Appendix 3H |
| 1 July 2026 | 2A · quoted issue | ZLD : ORDINARY FULLY PAID | 13.1M | Appendix 2A |
| 4 Dec 2025 | 3G · unquoted | ORDINARY FULLY PAID | 11.9M | Appendix 3G |
| 22 Oct 2025 | 3H · cancellation | ZLD : ORDINARY FULLY PAID | 11.9M | Appendix 3H |
| 1 Apr 2025 | 2A · quoted issue | ZLD : ORDINARY FULLY PAID | 11.9M | Appendix 2A |
Each filing states the count for the security it names, as at its own reference date and in the units of that filing — so the newest row (11.9M) need not equal the current count above (13.1M).
Securities on issue over time
Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.
Capital raises
1 cash raise in the last 24 months · 1 in the last 12 months
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
No option supply on record carries an exercise price to pay, so no share price switches any of it on. All 1.2M of it converts on something else — a hurdle that may never be met, or terms the filing does not price.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| ZLDAA | Options | Price-triggered, no exercise price stated | — | — | 1.2M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.
- ZLDAMconvertible notes1.8M2 July 2026 Appendix 2A
Director dealings
| Date | Director | Type | Shares | Options | Other | Value | Source |
|---|---|---|---|---|---|---|---|
| 1 July 2026 | Osagie Imasogie | Other | 1.3M | — | — | — | 3Y notice |
| 4 Dec 2025 | Dr. Donna Gentile O'Donnel | Other | — | 115k | 193k | $50k | 3Y notice |
| 4 Dec 2025 | Oludare Odumosu | Other | 132k | 240k | 387k | $100k | 3Y notice |
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.